Healthcare
Live Price
Offline$53.63
+4.56% today
1Y Change
+84.01%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Veracyte, Inc. (VCYT) is a Healthcare stock with a market cap of $2.64B and listed on NASDAQ. The stock last traded around $53.63 and up 84.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +16.0%, EPS growth of +162.5%, a dividend yield of 0.0%. What stands out right now is revenue +16.0%, EPS +162.5%, free cash flow +98.5% with operating margin 9.0% and ROIC 3.4%. Valuation already assumes a fairly strong business story at P/E 39.5 and price/sales 5.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VCYT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VCYT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VCYT Max Drawdown
-39.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VCYT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$219.5M
-26.0% YoY
FY Net Income
-$75.6M
-106.7% YoY
Free Cash Flow
-$37.0M
-3548.6% YoY
Revenue Growth
+16.0%
EPS Growth
+162.5%
Gross Margin
70.6%
Net Margin
12.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 517M | 446M | 361M | 297M | 220M |
| Gross Profit | 360M | 298M | 248M | 195M | 145M |
| Operating Income | 74M | 16M | -86M | -41M | -82M |
| EBITDA | 90M | 49M | -49M | -7M | -60M |
| Net Income | 66M | 24M | -74M | -37M | -76M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 363M | 239M | 216M | 154M | 173M |
| Total Assets | 1.4B | 1.3B | 1.1B | 1.2B | 1.2B |
| Total Liabilities | 96M | 124M | 71M | 81M | 91M |
| Shareholder Equity | 1.3B | 1.2B | 1.0B | 1.1B | 1.1B |
| Total Debt | 40M | 51M | 13M | 15M | 19M |
| Net Debt | -323M | -188M | -204M | -140M | -154M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32M
-519.7% YoY
Capital Expenditures
5M
+37.1% YoY
Free Cash Flow
37M
-3548.6% YoY
Key ratios
Gross Margin
70.6%
Operating Margin
9.0%
Net Margin
12.8%
ROE
5.3%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.